Targeting CDK4 with palbociclib or CDK4-specific siRNA has demonstrated substantial reductions in chondrosarcoma cell proliferation, migration, and invasion by inducing cell cycle arrest in the G1 phase, mainly through the CDK4/Rb signaling axis. This evidence concerns the gene CDK4 and chondrosarcoma.